“CHR Hansen supplies high-margin, mission-critical natural food ingredients that command strong pricing power and client loyalty. While facing historical headwinds in China and Europe, its approved merger with Novozymes to form Novonesis is currently being assessed to confirm it meets the fund's strict growth standards.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.